Candesartan Reddy
Angiotensin II Receptor Blocker (ARB) for Hypertension and Heart Failure
Quick facts about Candesartan Reddy
Key takeaways about Candesartan Reddy
- Effective blood pressure control: Candesartan is a well-established ARB that reduces systolic blood pressure by 10-15 mmHg on average, significantly lowering the risk of stroke, heart attack, and kidney disease
- Heart failure treatment: Proven to reduce hospitalisations and cardiovascular death in patients with heart failure and reduced ejection fraction, as shown in the CHARM programme trials
- Do not use in pregnancy: Candesartan can cause serious harm to the unborn baby, especially in the second and third trimesters; stop immediately if pregnancy is confirmed
- Monitor potassium and kidney function: Regular blood tests are recommended, particularly when starting treatment or adjusting the dose, as candesartan can raise potassium levels and affect kidney function
- Full effect develops over 4 weeks: While blood pressure starts to decrease within hours of the first dose, maximum therapeutic effect is usually reached after approximately 4 weeks of regular use
What Is Candesartan Reddy and What Is It Used For?
Candesartan Reddy is a prescription medication containing candesartan cilexetil, an angiotensin II receptor blocker (ARB) that treats high blood pressure (hypertension) and heart failure. It works by blocking the effects of angiotensin II, a hormone that narrows blood vessels and raises blood pressure.
Candesartan cilexetil is a prodrug, meaning it is converted into its active form, candesartan, during absorption from the gastrointestinal tract. Once active, candesartan selectively blocks the angiotensin II type 1 (AT1) receptor. Angiotensin II is one of the most potent vasoconstrictors in the body, and by blocking its receptor, candesartan causes blood vessels to relax and widen, reducing the resistance against which the heart must pump. This lowers blood pressure and decreases the workload on the heart.
The medication is approved for two primary indications. The first is essential hypertension in adults, and in children and adolescents aged 6 to 18 years, where lifestyle modifications alone have not adequately controlled blood pressure. The second is heart failure with reduced left ventricular systolic function (ejection fraction 40% or below) in adult patients, either as an alternative to angiotensin-converting enzyme (ACE) inhibitors in patients who cannot tolerate them, or as an add-on to existing ACE inhibitor therapy when symptoms persist.
Candesartan belongs to the ARB class of medications, which also includes losartan, valsartan, irbesartan, and telmisartan. These drugs are generally well-tolerated and are particularly valued because they do not cause the dry cough that is commonly associated with ACE inhibitors. The European Society of Cardiology (ESC) and the American Heart Association (AHA) both recommend ARBs as first-line treatment options for hypertension and as standard therapy for heart failure.
By effectively lowering blood pressure, candesartan helps prevent serious long-term complications of uncontrolled hypertension, including stroke, myocardial infarction (heart attack), kidney disease, and retinal damage. The landmark CHARM (Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity) programme, consisting of three parallel randomised controlled trials involving over 7,600 patients, demonstrated that candesartan significantly reduces cardiovascular death and hospitalisation for heart failure across a broad spectrum of patients.
Candesartan Reddy is a generic medicine that contains the same active substance and works in the same way as the original candesartan products. Generic medicines must meet the same strict standards for quality, safety, and efficacy as the originator medicine before they can be approved. This means Candesartan Reddy has been demonstrated to be bioequivalent to the reference product.
What Should You Know Before Taking Candesartan Reddy?
Before taking Candesartan Reddy, it is essential to inform your doctor about any existing medical conditions, particularly kidney disease, liver disease, or if you are pregnant or planning to become pregnant. Candesartan must not be used during pregnancy and requires careful monitoring of kidney function and electrolyte levels.
Contraindications
Candesartan Reddy must not be used in the following situations:
- Hypersensitivity to candesartan cilexetil or any of the excipients in the tablet formulation
- Pregnancy, particularly during the second and third trimesters (the medication should be stopped immediately if pregnancy is confirmed)
- Severe hepatic impairment or cholestasis (obstruction of bile flow), as candesartan is partly eliminated through the bile
- Concomitant use with aliskiren-containing products in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR below 60 ml/min/1.73 m²)
Warnings and Precautions
Several conditions require special caution and potentially closer monitoring when using Candesartan Reddy. Patients with renal artery stenosis (narrowing of the blood vessels supplying the kidneys) may experience worsening kidney function, including a rise in serum creatinine and blood urea nitrogen. In these patients, kidney function should be monitored closely during the initial weeks of treatment.
Patients with impaired kidney function should have their renal function and serum potassium levels monitored periodically. Candesartan can raise potassium levels (hyperkalaemia), particularly when used in combination with potassium-sparing diuretics, potassium supplements, or other medications that increase potassium levels. In patients with heart failure, treatment initiation may cause a drop in blood pressure, and the dose should be titrated carefully under medical supervision.
Patients who have experienced significant volume depletion or salt depletion (for example, from high-dose diuretic therapy, sodium-restricted diet, diarrhoea, or vomiting) may experience symptomatic hypotension when starting candesartan. It is advisable to correct any volume or salt depletion before initiating treatment, or to start with a lower dose.
Patients undergoing general anaesthesia or surgery should inform their anaesthetist that they are taking candesartan, as interaction with anaesthetic agents may result in a fall in blood pressure. Dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE inhibitors, ARBs, or aliskiren is generally not recommended because of the increased risk of hypotension, hyperkalaemia, and changes in renal function.
Candesartan Reddy must not be taken during pregnancy. Angiotensin II receptor blockers can cause fetal injury and death when used in the second and third trimesters. Effects include renal failure, oligohydramnios (low amniotic fluid), skull hypoplasia, hypotension, and death of the newborn. If you discover you are pregnant, stop candesartan immediately and contact your doctor. Women of childbearing potential should use effective contraception during treatment.
Pregnancy and Breastfeeding
Pregnancy: Candesartan is contraindicated during pregnancy. Treatment should not be initiated during pregnancy, and if pregnancy is detected during therapy, candesartan must be stopped immediately. During the first trimester, epidemiological evidence regarding teratogenicity is not conclusive, but a small increase in risk cannot be excluded. From the second trimester onward, ARBs are known to cause fetotoxicity, including reduced renal function, oligohydramnios, retardation of skull ossification, and neonatal renal failure, hypotension, and hyperkalaemia. If exposure has occurred from the second trimester, ultrasound examination of renal function and skull development is recommended.
Breastfeeding: It is not known whether candesartan is excreted in human breast milk. Because of the potential for adverse effects on the nursing infant, candesartan should not be used during breastfeeding. Alternative antihypertensive treatments with better-established safety profiles during breastfeeding should be chosen instead.
How Does Candesartan Reddy Interact with Other Drugs?
Candesartan Reddy can interact with several types of medications, most notably ACE inhibitors, potassium-sparing diuretics, lithium, NSAIDs, and aliskiren. These interactions can increase the risk of hyperkalaemia, kidney damage, or excessive blood pressure lowering. Always inform your doctor about all medications you are taking.
Drug interactions with candesartan are clinically important because they can lead to potentially serious adverse effects. The renin-angiotensin-aldosterone system (RAAS) is central to blood pressure regulation, and drugs that affect this system can have additive or synergistic effects when combined. Understanding these interactions helps prevent complications and ensures safe, effective use of candesartan.
Candesartan undergoes minimal hepatic metabolism and does not significantly inhibit or induce cytochrome P450 enzymes, which means it has a relatively low potential for pharmacokinetic drug interactions. However, the pharmacodynamic interactions related to its mechanism of action are clinically significant and require careful attention.
| Interacting Drug | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| ACE inhibitors (e.g., ramipril, enalapril) | Dual RAAS blockade | Increased risk of hyperkalaemia, renal impairment, and hypotension | Avoid combination, especially in diabetic nephropathy |
| Aliskiren | Dual RAAS blockade | Increased risk of hypotension, hyperkalaemia, and renal dysfunction | Contraindicated in diabetes or renal impairment (GFR <60) |
| Potassium-sparing diuretics (e.g., spironolactone, eplerenone) | Additive hyperkalaemia | Elevated serum potassium, potentially life-threatening cardiac arrhythmias | Monitor potassium closely; use with caution |
| Lithium | Reduced lithium excretion | Increased lithium serum levels, risk of lithium toxicity | Monitor lithium levels carefully; not recommended |
| NSAIDs (e.g., ibuprofen, naproxen) | Reduced antihypertensive effect | Attenuated blood pressure lowering; increased risk of renal impairment | Use with caution; monitor blood pressure and renal function |
| Potassium supplements | Additive hyperkalaemia | Elevated serum potassium | Monitor potassium; adjust supplementation as needed |
Major Interactions
Dual RAAS blockade with the combination of candesartan and an ACE inhibitor or aliskiren is one of the most important interactions to be aware of. The ONTARGET trial demonstrated that combining an ARB with an ACE inhibitor did not provide additional cardiovascular benefit but significantly increased the risk of hypotension, syncope, renal dysfunction, and hyperkalaemia. For this reason, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) both advise against dual RAAS blockade, and it is contraindicated in patients with diabetes or significant renal impairment.
Lithium toxicity is another significant concern. ARBs can reduce the renal excretion of lithium, leading to elevated serum levels and potentially dangerous toxicity symptoms including tremor, ataxia, and kidney damage. If the combination cannot be avoided, lithium levels should be monitored frequently and the lithium dose adjusted accordingly.
Minor Interactions
Thiazide diuretics such as hydrochlorothiazide are commonly combined with candesartan intentionally to achieve additive blood pressure lowering. Fixed-dose combination tablets are available for this purpose. While this is a therapeutic benefit, the combination may increase the risk of hypotension in volume-depleted patients and should be initiated with caution.
Calcium channel blockers such as amlodipine can also be safely combined with candesartan for additional blood pressure control. Current guidelines from the ESC/ESH recommend ARB plus calcium channel blocker as one of the preferred two-drug combinations for hypertension management.
What Is the Correct Dosage of Candesartan Reddy?
The usual starting dose of Candesartan Reddy for hypertension in adults is 8 mg once daily, with a recommended maintenance dose of 8 mg and a maximum dose of 32 mg daily. Dosing is individualised based on blood pressure response. The 4 mg tablet strength is particularly useful for initial dosing, paediatric use, and dose titration in heart failure.
Candesartan Reddy should be taken once daily, with or without food. The tablets should be swallowed whole with a glass of water. Consistent daily timing helps maintain steady blood levels and optimise blood pressure control throughout the 24-hour period. Candesartan has a long duration of action, which supports once-daily dosing. The antihypertensive effect is dose-dependent and becomes maximal within approximately 4 weeks of treatment initiation.
Adults – Hypertension
Standard Adult Dosing for Hypertension
- Starting dose: 8 mg once daily
- Usual maintenance dose: 8 mg once daily
- Dose adjustment: May be increased to 16 mg, then 32 mg if needed
- Maximum dose: 32 mg once daily
- Volume-depleted patients: Consider starting at 4 mg once daily
- Hepatic impairment (mild to moderate): Consider starting at 4 mg once daily
Adults – Heart Failure
Standard Adult Dosing for Heart Failure
- Starting dose: 4 mg once daily
- Dose titration: Double the dose at intervals of at least 2 weeks, as tolerated
- Target dose: 32 mg once daily
- Monitoring: Blood pressure, renal function, and serum potassium should be checked at each dose increase
Children and Adolescents (6–18 years)
Paediatric Dosing for Hypertension
Dosing is weight-based and should be prescribed by a specialist experienced in paediatric hypertension:
- Children weighing <50 kg: Starting dose 4 mg once daily; range 2–16 mg daily
- Children weighing ≥50 kg: Starting dose 4–8 mg once daily; range 4–32 mg daily
- Not recommended: For children under 6 years or those with a GFR below 30 ml/min/1.73 m²
Elderly Patients
No initial dose adjustment is generally required in elderly patients. However, elderly individuals may be more susceptible to hypotension and renal impairment, and careful dose titration with monitoring is advisable. A starting dose of 4 mg may be considered in frail elderly patients or those receiving multiple antihypertensive medications.
| Patient Group | Indication | Starting Dose | Maximum Dose |
|---|---|---|---|
| Adults | Hypertension | 8 mg once daily | 32 mg once daily |
| Adults | Heart failure | 4 mg once daily | 32 mg once daily |
| Children <50 kg | Hypertension | 4 mg once daily | 16 mg once daily |
| Children ≥50 kg | Hypertension | 4–8 mg once daily | 32 mg once daily |
| Elderly / volume-depleted | Hypertension | 4 mg once daily | 32 mg once daily |
| Hepatic impairment (mild-moderate) | Hypertension | 4 mg once daily | Titrate carefully |
Missed Dose
If you forget to take a dose of Candesartan Reddy, take it as soon as you remember on the same day. If it is already close to the time of your next dose, skip the missed dose entirely and resume your regular schedule the following day. Do not take a double dose to compensate for a forgotten one. Taking two doses at once could cause an excessive drop in blood pressure, potentially leading to dizziness, fainting, or impaired kidney function.
Overdose
Overdose with candesartan may cause symptomatic hypotension (dangerously low blood pressure) and dizziness. If overdose is suspected, the patient should be placed in the supine position with legs elevated and given intravenous normal saline to support blood pressure. Candesartan is not effectively removed by haemodialysis due to its high protein binding. There is no specific antidote for candesartan overdose; management is supportive and symptomatic. Contact a poison control centre or seek emergency medical attention immediately if you suspect an overdose.
What Are the Side Effects of Candesartan Reddy?
Candesartan Reddy is generally well-tolerated. The most common side effects include dizziness, headache, and respiratory infections. In heart failure patients, hyperkalaemia (raised potassium), low blood pressure, and changes in kidney function occur more frequently. Serious side effects such as angioedema are rare but require immediate medical attention.
Like all medicines, Candesartan Reddy can cause side effects, although not everyone experiences them. Most side effects are mild and tend to improve as the body adjusts to the medication. The side effect profile of candesartan is generally favourable compared to some older antihypertensive classes, and importantly, ARBs are significantly less likely to cause a dry cough than ACE inhibitors, which is one of the main reasons patients switch to this class of medication.
Clinical trials and post-marketing surveillance have identified the following side effects, categorised by frequency according to international conventions. Understanding these categories helps put the risk in perspective: "very common" means more than 1 in 10 people may be affected, while "rare" means fewer than 1 in 1,000 people.
Common Side Effects
- Dizziness or light-headedness
- Headache
- Respiratory infection (cold, sore throat, sinusitis)
- Hypotension (low blood pressure) – particularly in heart failure patients
- Hyperkalaemia (elevated potassium) – particularly in heart failure patients
- Impaired renal function – particularly in heart failure patients or those with pre-existing kidney disease
Uncommon Side Effects
- Back pain
- Nausea
- Fatigue or tiredness
- Elevated liver enzymes (usually mild and reversible)
- Diarrhoea
Rare Side Effects
- Angioedema (swelling of face, lips, tongue, or throat – seek immediate medical attention)
- Skin rash or urticaria (hives)
- Hepatitis (inflammation of the liver)
- Leucopenia (low white blood cell count)
- Neutropenia and agranulocytosis (severely low white blood cell counts)
- Hyponatraemia (low sodium levels)
Very Rare / Isolated Reports
- Abnormal liver function or hepatic failure
- Severe allergic reactions (anaphylaxis)
- Renal failure in susceptible patients
Contact your doctor or emergency services immediately if you experience swelling of the face, lips, tongue, or throat (angioedema), severe dizziness or fainting, significantly reduced urine output, or signs of a severe allergic reaction such as difficulty breathing. These side effects are rare but can be serious.
Most patients taking candesartan for hypertension experience few or no side effects. In clinical trials, the overall incidence of adverse events with candesartan was similar to that of placebo. Dizziness, the most commonly reported side effect, is typically mild and occurs most often during the first few days of treatment as the body adjusts to lower blood pressure. Staying well-hydrated and rising slowly from a seated or lying position can help minimise this effect.
For patients with heart failure, the incidence of hyperkalaemia, hypotension, and renal impairment is somewhat higher because these patients often have pre-existing cardiovascular and renal compromise and are frequently taking multiple medications that affect electrolyte balance. Regular monitoring through blood tests is essential in this group.
How Should You Store Candesartan Reddy?
Store Candesartan Reddy below 30°C in the original packaging to protect from moisture. Keep out of the reach and sight of children. Do not use the tablets after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety. Candesartan Reddy tablets should be stored at room temperature, not exceeding 30°C (86°F). Keep the tablets in their original blister packs or container to protect them from moisture and light. Avoid storing the medication in humid environments such as bathrooms.
Do not use Candesartan Reddy after the expiry date printed on the carton and blister foil. The expiry date refers to the last day of that month. If the tablets appear discoloured, crumbled, or damaged, do not take them. Do not dispose of medicines via wastewater or household waste; ask your pharmacist about appropriate disposal methods to help protect the environment.
Keep this medicine out of the sight and reach of children. A child accidentally ingesting adult cardiovascular medications can suffer serious consequences, including dangerously low blood pressure. If a child accidentally takes this medicine, seek medical advice immediately.
What Does Candesartan Reddy Contain?
Each Candesartan Reddy 4 mg tablet contains the active substance candesartan cilexetil 4 mg. The tablets also contain inactive ingredients (excipients) that help form the tablet and ensure proper absorption of the active substance.
The active substance in Candesartan Reddy is candesartan cilexetil. Each tablet contains 4 mg of candesartan cilexetil, which is rapidly hydrolysed to the pharmacologically active metabolite candesartan during gastrointestinal absorption. Candesartan cilexetil has the chemical formula C33H34N6O6 and a molecular weight of 610.66 g/mol.
The inactive ingredients (excipients) typically found in candesartan cilexetil tablets include:
- Lactose monohydrate – a filler/diluent derived from milk sugar
- Maize starch – aids in tablet disintegration
- Hydroxypropylcellulose – a binding agent
- Macrogol 8000 (polyethylene glycol) – enhances drug dissolution
- Carmellose calcium – a disintegrant that helps the tablet break apart
- Magnesium stearate – a lubricant used in tablet manufacturing
- Iron oxide (E172) – colourant (may vary by tablet strength)
Candesartan Reddy tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Frequently Asked Questions About Candesartan Reddy
Candesartan Reddy is used to treat high blood pressure (hypertension) in adults and in children aged 6 to 18 years. It is also used to treat heart failure in adults with reduced heart muscle function. By lowering blood pressure, candesartan reduces the long-term risk of serious cardiovascular events including stroke, heart attack, and kidney damage. In heart failure, it helps reduce hospitalisations and improves symptoms.
No. Candesartan Reddy must not be used during pregnancy. It can cause serious harm to the developing baby, particularly in the second and third trimesters, including kidney damage, low amniotic fluid, and potentially fetal death. If you become pregnant while taking candesartan, stop the medication immediately and consult your doctor for a safer alternative.
The most common side effects include dizziness, headache, and respiratory infections such as colds. In patients with heart failure, low blood pressure, elevated potassium levels, and changes in kidney function may also occur. Most side effects are mild and temporary. In clinical trials, the overall rate of side effects with candesartan was similar to placebo.
Alcohol can lower blood pressure and may increase the blood pressure-lowering effect of candesartan, potentially causing dizziness or fainting. While moderate alcohol consumption is not strictly contraindicated, it is advisable to limit alcohol intake, especially when starting treatment or after a dose increase. If you experience dizziness, avoid alcohol until the symptoms settle.
Candesartan begins to lower blood pressure within 2 hours of the first dose, with peak effects at 4-6 hours. However, the full blood pressure-lowering effect develops gradually over approximately 4 weeks of regular daily use. Your doctor may check your blood pressure and adjust your dose during this period. It is important to continue taking candesartan every day, even if you feel well, as high blood pressure often has no noticeable symptoms.
You should not stop taking candesartan without consulting your doctor. While there is no known rebound hypertension (a sudden dangerous rise in blood pressure) with ARBs, stopping treatment means your blood pressure will gradually return to pre-treatment levels. Uncontrolled hypertension increases the risk of stroke, heart attack, and kidney damage. If you are experiencing side effects, speak to your doctor about adjusting your dose or switching to an alternative medication.
References
- European Medicines Agency (EMA). Candesartan cilexetil – Summary of Product Characteristics. Available at: www.ema.europa.eu
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet. 2003;362(9386):759-766. doi:10.1016/S0140-6736(03)14282-1
- McMurray JJ, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362(9386):767-771.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777-781.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127-e248.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [NG136]. Updated 2022. Available at: www.nice.org.uk/guidance/ng136
- World Health Organization (WHO). Model List of Essential Medicines – 23rd list. 2023. Available at: www.who.int
- ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine. 2008;358(15):1547-1559.
- British National Formulary (BNF). Candesartan cilexetil. Available at: bnf.nice.org.uk
About iMedic Medical Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians, clinical pharmacologists, and medical researchers with expertise in cardiovascular medicine and pharmacotherapy. Our editorial process follows international standards for medical content, including the GRADE evidence framework, and adheres to guidelines from the WHO, ESC, AHA, and NICE.
All content is reviewed by board-certified physicians with specialist training in cardiology and clinical pharmacology. Our team follows the latest international guidelines to ensure accuracy and clinical relevance.
iMedic maintains strict editorial independence. We receive no funding from pharmaceutical companies and have no conflicts of interest. All medical claims are supported by peer-reviewed evidence. Read our full editorial policy.